Pfizer Inc. (ETR:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 121.89B |
| Revenue (ttm) | 53.69B |
| Net Income (ttm) | 8.41B |
| Shares Out | n/a |
| EPS (ttm) | 1.48 |
| PE Ratio | 14.50 |
| Forward PE | 8.61 |
| Dividend | 1.53 (7.14%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 46,025 |
| Average Volume | 62,157 |
| Open | 21.55 |
| Previous Close | 21.42 |
| Day's Range | 21.48 - 21.62 |
| 52-Week Range | 18.57 - 26.54 |
| Beta | 0.42 |
| RSI | 46.65 |
| Earnings Date | Feb 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
How Safe Is Pfizer's Dividend As 2026 Begins?
Income investors probably don't need to worry about a dividend cut from Pfizer in the new year.
2 Predictions for Pfizer in 2026
The company's prospects are stronger than its stock-market performance in 2025 suggests.
Pfizer 2026: The Reset Year
Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read my latest analysis of PFE stock.
Should You Buy Pfizer While It's Under $30?
It might not pay off immediately, but it could, eventually.
Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026
Ares Capital offers an especially juicy dividend. Energy Transfer has an impressive track record of increasing its distribution each quarter.
Where Will Pfizer Be in 5 Years?
Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.
After Hours Most Active for Dec 31, 2025 : PATH, NVDA, IUSV, AAPL, SNV, PNFP, ACHR, T, ACWX, AMZN, SOC, PFE
The NASDAQ 100 After Hours Indicator is up .46 to 25,250.31. The total After hours volume is currently 112,218,174 shares traded.The following are the most active stocks for the after hours session: U...
RECS, VOX, PFE, SCHW: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Columbia Research Enhanced Core ETF (Symbol: RECS) where we have detec...
The Year-End 2025 Biotech Rally And What It Means For 2026
Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...
Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
Pfizer and GSK Lead 2026 U.S. Drug Price Hikes
Pfizer and GSK Lead 2026 U.S. Drug Price Hikes
Pfizer (PFE) and GSK (GSK) Plan Significant Drug Price Increases
Pfizer (PFE) and GSK (GSK) Plan Significant Drug Price Increases
3 ultra-high-yield stocks to consider for $300 of dividend income in 2026
Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully ve...
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report
2 Unstoppable Dividend Stocks to Double Up on Right Now
Both companies have faced some headwinds recently, but the core businesses and dividend payouts remain strong. Blackstone is the top alternative asset manager in the world and operates as a premier gl...
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
After Hours Most Active for Dec 30, 2025 : RKT, NVDA, IXUS, T, ORCL, MRVL, PFE, KVUE, CSCO, NU, AAPL, INTC
The NASDAQ 100 After Hours Indicator is down -.54 to 25,462.02. The total After hours volume is currently 94,180,282 shares traded.The following are the most active stocks for the after hours session:...
SA analyst upgrades/downgrades: PLTR, TGT, NET, PFE
Want $300 in Super-Safe Dividend Income in 2026? Invest $2,670 Into the Following 3 Ultra-High-Yield Stocks.
Over the last half-century, dividend stocks have notably outperformed non-payers -- and have done so while being less volatile than the benchmark S&P 500. While some ultra-high-yielding income stocks ...
After Hours Most Active for Dec 29, 2025 : LINE, GENI, NVDA, FUN, CMCSA, PFE, CSCO, PEP, OPEN, O, XOM, KBR
The NASDAQ 100 After Hours Indicator is down -3.57 to 25,521.99. The total After hours volume is currently 89,566,039 shares traded.The following are the most active stocks for the after hours session...
Pfizer (PFE) Sees Increased Bearish Sentiment Among Option Traders
Pfizer (PFE) Sees Increased Bearish Sentiment Among Option Traders
The Smartest Dividend Stocks to Buy With $3,000 Right Now
These businesses have both steadily increased their payouts. Lowe's is focusing on the lucrative professional contractor market.
Pfizer: Adjusted EPS Masks How Bad 2026 Really Looks
Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth. Read why PFE stock is a Sell.
Notable healthcare headlines for the week: J&J, Pfizer, and Novo Nordisk in focus
3 Drug Stocks to Buy at a Discount
Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight ...